Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Innovative Pharmaceutical Biotech ( (HK:0399) ).
Innovative Pharmaceutical Biotech Limited announced that its subsidiary, Fosse Bio-Engineering Development Limited, has entered into an agency agreement with Terry Bio Pharmaceutical Co., Ltd. This agreement appoints Terry Bio Pharmaceutical as the exclusive agent to market, distribute, sell, and promote Fosse Bio-Engineering’s oral pancreatic health products in Thailand for a period of six years, with an automatic renewal for another six years. This strategic move aims to expand the company’s market presence in Thailand, contingent on obtaining necessary approvals by May 2025.
More about Innovative Pharmaceutical Biotech
Innovative Pharmaceutical Biotech Limited is an investment holding company primarily engaged in the trading of beauty equipment and products, as well as the research, development, and commercialization of oral insulin products.
YTD Price Performance: -13.94%
Average Trading Volume: 999,948
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$326.2M
For detailed information about 0399 stock, go to TipRanks’ Stock Analysis page.